Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glycopyrronium bromide for non-drug induced hypersalivation in children
2014-001631-36Phase 2Completed
- Sponsor
- Colonis Pharmaceuticals
- Start
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hypersalivation and Neurodevelopmental disorder (NDD) comparing Glycopyrronium bromide with Placebo / then glycopyrronium bromide (2 arms). Primary endpoint: Primary response at 8 weeks on modified Teacher's Drooling Scale. Started Sep 2014; status: completed.
02
Drugs
glycopyrronium
03
Conditions
hypersalivationNeurodevelopmental disorder (NDD)
Beyond the preview
Go deeper on 2014-001631-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001631-36.